Heron Therapeutics Inc (NASDAQ:HRTX) saw unusually large options trading on Wednesday. Stock traders acquired 5,322 call options on the company. This is an increase of 678% compared to the average daily volume of 684 call options.
A number of institutional investors have recently added to or reduced their stakes in HRTX. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Heron Therapeutics by 24.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,747 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 929 shares during the last quarter. Jefferies Group LLC acquired a new position in Heron Therapeutics in the third quarter valued at $202,000. Verition Fund Management LLC acquired a new position in Heron Therapeutics in the third quarter valued at $208,000. Stephens Inc. AR acquired a new position in Heron Therapeutics in the fourth quarter valued at $208,000. Finally, Pacer Advisors Inc. acquired a new position in Heron Therapeutics in the third quarter valued at $223,000.
A number of equities analysts have recently weighed in on HRTX shares. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price target on shares of Heron Therapeutics in a report on Monday, December 31st. Stifel Nicolaus reissued a “buy” rating and issued a $54.00 price target on shares of Heron Therapeutics in a report on Friday, February 22nd. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target (down from $66.00) on shares of Heron Therapeutics in a report on Wednesday, January 16th. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Finally, ValuEngine raised Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and an average target price of $51.82.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Friday, February 22nd. The biotechnology company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.17). The business had revenue of $28.84 million during the quarter, compared to analyst estimates of $28.05 million. Heron Therapeutics had a negative net margin of 230.84% and a negative return on equity of 54.98%. Equities analysts predict that Heron Therapeutics will post -1.52 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2019/03/21/heron-therapeutics-sees-unusually-high-options-volume-hrtx.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.